JPS596845B2 - 抗血友病因子の収率改良法 - Google Patents

抗血友病因子の収率改良法

Info

Publication number
JPS596845B2
JPS596845B2 JP48054039A JP5403973A JPS596845B2 JP S596845 B2 JPS596845 B2 JP S596845B2 JP 48054039 A JP48054039 A JP 48054039A JP 5403973 A JP5403973 A JP 5403973A JP S596845 B2 JPS596845 B2 JP S596845B2
Authority
JP
Japan
Prior art keywords
ahf
heparin
plasma
factor
glycine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
JP48054039A
Other languages
English (en)
Japanese (ja)
Other versions
JPS4956695A (fr
Inventor
エフ フエケテ ラジヨス
エル ホルスト ステイ−ブン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxter International Inc
Original Assignee
Baxter Travenol Laboratories Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Travenol Laboratories Inc filed Critical Baxter Travenol Laboratories Inc
Publication of JPS4956695A publication Critical patent/JPS4956695A/ja
Publication of JPS596845B2 publication Critical patent/JPS596845B2/ja
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/829—Blood
    • Y10S530/83—Plasma; serum

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Golf Clubs (AREA)
JP48054039A 1972-05-17 1973-05-14 抗血友病因子の収率改良法 Expired JPS596845B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US00254148A US3803115A (en) 1972-05-17 1972-05-17 Stabilization of ahf using heparin
US254148 1972-05-17

Publications (2)

Publication Number Publication Date
JPS4956695A JPS4956695A (fr) 1974-06-01
JPS596845B2 true JPS596845B2 (ja) 1984-02-15

Family

ID=22963114

Family Applications (1)

Application Number Title Priority Date Filing Date
JP48054039A Expired JPS596845B2 (ja) 1972-05-17 1973-05-14 抗血友病因子の収率改良法

Country Status (18)

Country Link
US (2) US3803115A (fr)
JP (1) JPS596845B2 (fr)
AT (1) AT344881B (fr)
AU (1) AU465351B2 (fr)
BE (1) BE799525A (fr)
CA (1) CA1007986A (fr)
CH (1) CH630804A5 (fr)
DE (1) DE2324717C3 (fr)
DK (1) DK136016B (fr)
ES (1) ES414823A1 (fr)
FR (1) FR2184898B1 (fr)
GB (1) GB1372515A (fr)
IL (1) IL42221A (fr)
IT (1) IT1061433B (fr)
NL (1) NL7306806A (fr)
NO (1) NO142381C (fr)
SE (1) SE430020B (fr)
ZA (1) ZA733138B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3920625A (en) * 1973-06-19 1975-11-18 Kabi Ab Isolation of coagulation factors from biological material using cross linked sulfated, sulfonated carbohydrates
US4022758A (en) * 1973-06-19 1977-05-10 Ab Kabi Isolation of coagulation factors I and VIII from biological material
US3973002A (en) * 1974-04-12 1976-08-03 E. R. Squibb & Sons, Inc. Antihemophilic factor
US4069216A (en) * 1975-06-16 1978-01-17 Edward Shanbrom, Inc. Simplified methods for preparation of very high purity Factor VIII concentrate
US4089944A (en) 1975-12-22 1978-05-16 Baxter Travenol Laboratories, Inc. Rapidly solubilized AHF composition and process for preparing same
JPS52125609A (en) * 1976-04-09 1977-10-21 Green Cross Corp:The Purification of agglutination factor viii
DE2624373C2 (de) * 1976-05-31 1983-02-03 Arnold Dr. 8782 Karlstadt Seufert Verfahren zur Herstellung von steril filtriertem Kryopräzipilat mit einer Anreicherung des Faktors VIII
CA1074698A (fr) * 1977-12-19 1980-04-01 Gail A. Rock Methode pour augmenter la production de facteur antihemophilique viii dans le sang et le plasma
AT359646B (de) * 1979-04-19 1980-11-25 Immuno Ag Verfahren zur herstellung von nebenwirkungs- freien plasmafraktionen
US4278594A (en) * 1979-06-19 1981-07-14 David Amrani Process for separation and isolation of AHF, von Willebrand's ristocetin cofactor (VWF:RCF) and fibronectin from blood plasma
US4210580A (en) * 1979-06-19 1980-07-01 David Amrani Process for separation and isolation of AHF and fibronectin from blood plasma
DE3163003D1 (en) * 1980-01-18 1984-05-17 Canadian Red Cross Method of obtaining factor viii
US4289691A (en) * 1980-01-18 1981-09-15 The Canadian Red Cross Society Method of obtaining intermediate purity factor VIII
US4305871A (en) * 1980-09-02 1981-12-15 Edward Shanbrom Method of selectively increasing yield and purity of certain cryoprecipitate proteins by heating
CA1178887A (fr) * 1981-10-01 1984-12-04 Gail A. Rock Concentres de facteur viii prepares a partir de plasma heparinise grace a une technique de precipitation a froid
US4397841A (en) 1982-06-28 1983-08-09 Monsanto Company Production of blood coagulation factor VIII:C
US5149787A (en) * 1984-05-22 1992-09-22 The Blood Center Research Foundation Method for maintaining intact, non-degraded factor VIII/von-Willebrand factor during blood processing
US4543210A (en) 1984-10-04 1985-09-24 Miles Laboratories, Inc. Process for producing a high purity antihemophilic factor concentrate
GB8505882D0 (en) * 1985-03-07 1985-04-11 Central Blood Lab Authority Purification of blood coagulation factor viii
EP0238701B1 (fr) * 1986-03-27 1992-03-18 Octapharma AG Procédé de production d'un facteur anti-hémophilique hautement purifié
USH1509H (en) * 1989-06-09 1995-12-05 Eran; Harutyun Heparin enhanced process for separating antihemophilic factor (Factor VIII) and fibronectin from cryoprecipitate
FR2651437A1 (fr) * 1989-09-05 1991-03-08 Lille Transfusion Sanguine Procede de preparation de concentre du complexe facteur viii-facteur von willebrand de la coagulation sanguine a partir de plasma total.
FR2657884B1 (fr) * 1990-02-05 1994-09-02 Tm Innovation Procede pour la preparation du facteur viii humain et d'analogues du facteur viii.
IT1248723B (it) * 1990-06-12 1995-01-26 Scalvo S P A Processo per la purificazione del fattore viii e fattore viii ottenuto con tale processo
US5278289A (en) * 1991-11-12 1994-01-11 Johnson Alan J Antihemophilic factor stabilization
US5659017A (en) * 1995-11-07 1997-08-19 Alpha Therapeutic Corporation Anion exchange process for the purification of Factor VIII
US6881731B1 (en) * 2000-10-23 2005-04-19 Shanbrom Technologies, Llc Enhancers for microbiological disinfection
US7411006B2 (en) * 2000-10-23 2008-08-12 Shanbrom Technologies, Llc Enhanced production of blood clotting factors and fibrin fabric
US8389687B2 (en) * 2000-10-23 2013-03-05 Shanbrom Technologies, Llc Polyvinylpyrrolidone cryoprecipitate extraction of clotting factors
US7297716B2 (en) * 2000-10-23 2007-11-20 Shanbrom Technologies, Llc Enhanced production of blood components, blood cells and plasma without freezing
EP1363616A1 (fr) * 2001-02-07 2003-11-26 Shanbrom Technologies, LLC Acide carboxylique, par exemple acide citrique, utilise pour la desinfection ou l'amelioration de la production de produits sanguins, tels que le plasma, le cryoprecipite et/ou les plaquettes

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3631018A (en) * 1970-05-01 1971-12-28 Baxter Laboratories Inc Production of stable high-potency human ahf using polyethylene glycol and glycine to fractionate a cryoprecipitate of ahf concentrate

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2867567A (en) * 1955-01-21 1959-01-06 Nat Res Dev Process of preparing anti-haemophilic globulin
DE1949314U (de) 1966-05-07 1966-11-10 Braun Fa B Bohrdraht-bereitschaftskasten.
BE713764A (fr) 1967-05-01 1968-09-16 Baxter Travenol Lab
US3652530A (en) * 1967-08-28 1972-03-28 American Nat Red Cross Antihemophilic factor prepared from blood plasma using polyethylene glycol
US3560475A (en) * 1969-06-19 1971-02-02 Baxter Laboratories Inc Prothrombin complex prepared by precipitation with polyethylene glycol
US3682881A (en) * 1970-10-02 1972-08-08 Baxter Laboratories Inc Fractionation of plasma using glycine and polyethylene glycol

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3631018A (en) * 1970-05-01 1971-12-28 Baxter Laboratories Inc Production of stable high-potency human ahf using polyethylene glycol and glycine to fractionate a cryoprecipitate of ahf concentrate

Also Published As

Publication number Publication date
DK136016C (fr) 1978-01-02
AT344881B (de) 1978-08-10
DK136016B (da) 1977-08-01
NO142381C (no) 1980-08-13
ZA733138B (en) 1974-03-27
SE430020B (sv) 1983-10-17
AU5584973A (en) 1974-11-21
DE2324717C3 (de) 1983-12-01
DE2324717B2 (de) 1980-01-03
NO142381B (no) 1980-05-05
FR2184898A1 (fr) 1973-12-28
FR2184898B1 (fr) 1976-11-05
ES414823A1 (es) 1976-02-01
IL42221A0 (en) 1973-07-30
USRE29698E (en) 1978-07-11
DE2324717A1 (de) 1973-12-13
GB1372515A (en) 1974-10-30
ATA433573A (de) 1975-04-15
IT1061433B (it) 1983-02-28
CH630804A5 (de) 1982-07-15
IL42221A (en) 1977-04-29
AU465351B2 (en) 1975-09-25
CA1007986A (en) 1977-04-05
US3803115A (en) 1974-04-09
BE799525A (fr) 1973-08-31
JPS4956695A (fr) 1974-06-01
NL7306806A (fr) 1973-11-20

Similar Documents

Publication Publication Date Title
JPS596845B2 (ja) 抗血友病因子の収率改良法
EP0638091B1 (fr) Solubilisation et stabilisation ameliorees du complexe du facteur viii
US3631018A (en) Production of stable high-potency human ahf using polyethylene glycol and glycine to fractionate a cryoprecipitate of ahf concentrate
CA1329542C (fr) Formulation de plasma et de proteines recombinantes dans des milieux a faible force ionique
US6541518B2 (en) Enhanced production of safe plasma preparations
US4327086A (en) Process for heat treatment of aqueous solution containing human blood coagulation factor XIII
US4203891A (en) Method of collecting anti-hemophilic factor VIII from blood and blood plasma using heparin or sodium heparin
US4478829A (en) Pharmaceutical preparation containing purified fibronectin
US3682881A (en) Fractionation of plasma using glycine and polyethylene glycol
EP0314095A1 (fr) Formulation de protéines recombinantes ou provenant du plasma dans un milieu de haute force ionique
RU96119971A (ru) Способ получения биологического клея, изготовленного из концентрированных коагулирующих факторов посредством "высаливания"
JPH0676337B2 (ja) 高純度抗血友病性因子濃縮物の製造法
US4727059A (en) Fibronectin solution suitable for use in humans and process for its preparation
CA1196281A (fr) Stabilisation des proteines plasmatiques par la chaleur
US7297716B2 (en) Enhanced production of blood components, blood cells and plasma without freezing
JPH06511018A (ja) 血漿分画精製法
JPH06505494A (ja) Ｉｘ因子の調製
CA1182748A (fr) Methode pour synthetiser le facteur d'activation viii procoagulant
US4822872A (en) Method of purifying factor VIII
JPS61189228A (ja) 血液凝固第８因子製剤の製法
AU2002248415B2 (en) Carboxylic Acid Such as Citric Acid for Disinfecting or Enhacing the Production of Blood Products Such as Plasma, Cryoprecipitate and/or Platelet
JP2916947B2 (ja) Ｃｐｂ―ｉの安定化方法及び製剤組成物
AU2002248415A1 (en) Carboxylic Acid Such as Citric Acid for Disinfecting or Enhacing the Production of Blood Products Such as Plasma, Cryoprecipitate and/or Platelet
US20080281081A1 (en) Polyvinyl Pyrollidone Cryoprecipitate Extraction of Clotting Factors
SE443293B (sv) Blodfraktionsframstellning